Liposomal Bupivacaine in Perioperative Analgesia: A Comprehensive Review of Clinical Efficacy, Safety, and Economic Context

Abstract

Purpose of Review

Effective postoperative pain management remains a critical component of perioperative care, with growing emphasis on opioid-sparing multimodal analgesic strategies. Liposomal bupivacaine, a long-acting formulation of bupivacaine utilizing DepoFoam multivesicular liposome technology, was developed to provide prolonged local anesthetic delivery and improve postoperative analgesia. Since its initial FDA approval, its use has expanded across a broad range of surgical specialties and regional anesthesia techniques. This review examines the pharmacology, clinical efficacy, safety profile, and economic considerations surrounding liposomal bupivacaine use in perioperative practice.

Recent Findings

Current evidence demonstrates that liposomal bupivacaine may reduce postoperative opioid consumption and improve recovery-related outcomes in select patient populations and procedures; however, its superiority over conventional local anesthetic strategies remains inconsistent. Comparisons with optimized multimodal analgesic regimens, including standard bupivacaine with adjuvants and continuous peripheral nerve catheters, highlight important limitations in demonstrating clinically meaningful benefit. Additionally, the higher acquisition cost necessitates careful consideration of procedure-specific factors, institutional pathways, and patient selection.

Summary

Ultimately, liposomal bupivacaine should be viewed as a specialized component of multimodal analgesia rather than a universal replacement for existing pain management approaches. Future research should focus on identifying patient populations and surgical settings most likely to derive meaningful clinical and economic benefits.

Introduction

Acute postoperative pain remains a significant and persistent challenge in perioperative care, with up to 75% of surgical patients reporting moderate to severe pain despite the widespread adoption of multimodal analgesic strategies [1, 2]. Historically, opioids have served as the cornerstone of postoperative pain management; however, their use has contributed to a growing public health crisis. These concerns have prompted increasing emphasis on opioid-sparing approaches within perioperative medicine.

One strategy is the incorporation of extended-release local anesthetic formulations, such as liposomal bupivacaine (EXPAREL), into multimodal analgesic pathways. Although widely adopted across multiple surgical specialties, its incremental clinical benefit compared with conventional local anesthetic strategies remains uncertain. This review aims to synthesize the current evidence regarding its pharmacologic properties, clinical efficacy across surgical specialties, opioid-sparing potential, safety profile, and cost-effectiveness to better define its role in modern multimodal analgesia strategies.

Background

The Burden of Post-Surgical Pain and Opioid Use

Acute postoperative pain affects up to 75% of surgical patients, highlighting the ongoing limitations of current analgesic strategies [1, 2]. Traditionally, opioids have been the mainstay of postoperative pain management. Among opioid-naïve patients prescribed opioids following surgery, approximately 6.5% continue to use opioids for one year postoperatively, and 0.6% ultimately develop opioid use disorder [3]. The drivers of this epidemic are multifactorial, including the inherent addictive potential of opioids, aggressive pharmaceutical marketing, the now-discredited “Pain as the Fifth Vital Sign” initiative, and persistently excessive prescribing practices at hospital discharge [2].

Beyond the risk of persistent use and addiction, opioid therapy is associated with a range of dose-dependent adverse effects that complicate postoperative recovery. These include respiratory depression, central nervous system depression, delayed gastrointestinal motility, and an increased risk of postoperative ileus. Furthermore, perioperative opioid exposure may induce acute tolerance, opioid-induced hyperalgesia, and withdrawal symptoms upon abrupt discontinuation [1]. The risk of misuse escalates with continued exposure, with each prescription refill increasing the likelihood of misuse by 44% and each additional week of therapy increasing risk by 20%.^2,3 Collectively, these concerns have driven the ongoing search for effective, opioid-sparing analgesic strategies.

Overview of Liposomal Bupivacaine

Extended-release local anesthetics, such as liposomal bupivacaine (EXPAREL) is a possible strategy. EXPAREL is a formulation of bupivacaine hydrochloride encapsulated within multivesicular liposomes designed to provide sustained postoperative analgesia. This formulation allows for the gradual release of bupivacaine over time, with reported analgesic effects lasting up to 72 h following a single administration [4, 5]. While the mechanism of action is consistent with conventional local anesthetics, namely, blockade of voltage-gated sodium channels to inhibit nerve impulse conduction, the liposomal delivery system distinguishes it from standard bupivacaine by prolonging drug release and potentially extending analgesic duration [4].

Regulatory History and Expanding Indications

Since its initial approval by the U.S. Food and Drug Administration in 2011 for surgical site infiltration in procedures such as bunionectomy and hemorrhoidectomy, the indications for liposomal bupivacaine have expanded to include peripheral nerve blocks, including interscalene brachial plexus, sciatic (popliteal), and adductor canal blocks in adults [5]. Additional approval has been granted for pediatric use in patients aged six years and older, supported by pharmacokinetic and safety data, with dosing recommendations based on weight. These expanded indications have contributed to increasing adoption across a wide range of surgical specialties.

Clinical Efficacy and Ongoing Debate

Despite its theoretical advantages, the clinical efficacy of liposomal bupivacaine relative to conventional local anesthetics remains an area of ongoing debate. Evidence from randomized controlled trials and systematic reviews has been inconsistent. A large review of 76 randomized trials found that only a minority of infiltration studies demonstrated clinically meaningful benefit over standard local anesthetics, while comparisons with peripheral nerve blocks often favored traditional techniques [6]. Similarly, a Cochrane review concluded that although liposomal bupivacaine may reduce postoperative pain compared to placebo, it does not consistently demonstrate superiority over bupivacaine hydrochloride [7]. More recent meta-analysis suggest modest improvements in pain scores persisting up to 72 h, though without corresponding reductions in opioid consumption [8]. Given these mixed findings, the role of liposomal bupivacaine in contemporary perioperative analgesia remains uncertain.

Pharmacology and Technology

DepoFoam^® Technology and Liposomal Structure

EXPAREL is formulated using DepoFoam^® technology, a multivesicular liposomal drug delivery system that differs fundamentally from conventional unilamellar or multilamellar liposomes. Rather than a single or concentric lipid bilayer, DepoFoam particles consist of hundreds of discrete, non-concentric aqueous chambers separated by lipid bilayer septa, forming a honeycomb-like internal architecture [9–11]. These particles, typically measuring 24–31 μm in diameter, contain large internal aqueous volumes that allow for encapsulation of substantial quantities of drug within relatively small injection volumes [12].

This structural design confers several pharmacologic advantages, including high drug encapsulation efficiency, mechanical stability, and the ability to incorporate both hydrophilic and lipophilic compounds [9, 11]. The DepoFoam platform has been applied to multiple therapeutic agents, including cytarabine and morphine, in addition to bupivacaine, demonstrating its versatility as a sustained-release delivery system [11, 13]. In the case of liposomal bupivacaine, this architecture enables prolonged local anesthetic delivery at the site of administration.

Mechanism of Drug Release

Drug release from DepoFoam particles occurs through a combination of lipid membrane erosion and passive diffusion across lipid bilayers [11, 12]. As the lipid gradually degrades, encapsulated bupivacaine is released in a controlled and sustained manner. This dual mechanism allows for extended drug delivery over prolonged periods, which can be modulated by alterations in lipid composition and manufacturing parameters [11–13].

For liposomal bupivacaine specifically, this results in a prolonged duration of action, with clinically relevant analgesia reported for up to 72–96 h following a single administration [4, 5]. The biodegradable nature of the lipid membranes ensures eventual breakdown of the delivery system, with complete release of the encapsulated drug over time [9]. This controlled-release profile distinguishes liposomal bupivacaine from conventional formulations, which are characterized by rapid systemic absorption and shorter durations of action.

Pharmacokinetics

A defining feature of liposomal bupivacaine is its unique bimodal pharmacokinetic profile, which contrasts with the single peak observed following administration of standard bupivacaine hydrochloride [14]. Following injection, an initial plasma concentration peak occurs within approximately one hour, reflecting early systemic absorption of unencapsulated or surface-associated drug. This is followed by a second, delayed peak occurring between 12 and 36 h, corresponding to the gradual release of bupivacaine from the liposomal structure [14, 15].

Compared to standard bupivacaine, liposomal formulations demonstrate a lower initial peak plasma concentration (Cmax), typically ranging from 129 to 495 ng/mL depending on the site of administration, and a prolonged time to maximum concentration (Tmax) due to sustained absorption [9–11]. Detectable plasma concentrations may persist for 96 to 168 h, with elimination half-lives ranging from approximately 11 to 28 h which is substantially longer than the 2.7-hour half-life associated with conventional bupivacaine [10, 12]. Notably, pharmacokinetic parameters vary by injection site and technique, with peripheral nerve blocks demonstrating more prolonged systemic exposure compared to local infiltration.

Clinical studies highlight significant interpatient variability in systemic absorption. For example, intercostal nerve blocks have demonstrated median Tmax values of approximately 24 h with wide variability, while sciatic nerve blocks exhibit biphasic peaks with late-phase concentrations approximately 30–50% lower than initial peaks [16, 17]. Importantly, systemic plasma concentrations do not correlate directly with analgesic efficacy, which is primarily mediated by local tissue drug concentrations rather than circulating levels.

Metabolism, Excretion, and Safety Considerations

Once released from the liposomal carrier and absorbed systemically, bupivacaine undergoes distribution, metabolism, and excretion like standard formulations. It is primarily metabolized hepatically via aromatic hydroxylation and N-dealkylation, with renal excretion of metabolites.

The risk of local anesthetic systemic toxicity (LAST) remains an important consideration with liposomal bupivacaine. The controlled-release mechanism is thought to reduce peak plasma concentrations and thereby lower the risk of toxicity relative to standard bupivacaine; however, this risk is not eliminated [18–20]. Established toxicity thresholds for bupivacaine are approximately 2 µg/mL for neurologic toxicity and 4 µg/mL for cardiotoxicity [16, 17, 20]. Across multiple pharmacokinetic studies, plasma concentrations following liposomal bupivacaine administration have consistently remained well below these thresholds, even in high-dose or bilateral administration scenarios [16, 17, 20].

Despite this favorable pharmacokinetic profile, cases of LAST, including seizures and cardiac arrest, have been reported, and pharmacovigilance data demonstrate a significant association between liposomal bupivacaine and reported toxicity events [18, 19]. These findings underscore the need for continued vigilance, adherence to dosing guidelines, and readiness to initiate treatment with advanced cardiac life support and intravenous lipid emulsion therapy when indicated. Additionally, due to prolonged systemic absorption, the U.S. Food and Drug Administration recommends extended monitoring for signs of toxicity for up to 96–168 h following administration.

Clinical Efficacy by Surgical Specialty

Orthopedics

In total knee arthroplasty (TKA), the efficacy of liposomal bupivacaine remains mixed despite extensive study. Early evidence, including a systematic review and meta-analysis of periarticular injection (PAI) techniques, found no significant differences between liposomal and conventional multimodal PAI regimens in pain scores, opioid consumption, length of stay, or functional outcomes [21]. More recent randomized controlled trials have demonstrated similarly variable findings, with some showing no differences in pain, range of motion, or opioid use compared with levobupivacaine alone, aside from delayed time to first analgesic request [22]. Conversely, other studies report modest reductions in early postoperative pain and opioid consumption, although these benefits are not sustained and frequently fail to meet thresholds for clinical significance [23, 24]. In total hip arthroplasty (THA), the evidence base is more limited but follows a similar pattern, with meta-analyses demonstrating modest early pain reduction that is not consistently maintained and does not reliably translate into decreased opioid use [25]. Some studies also report secondary benefits such as reduced length of stay and postoperative nausea, though these findings are derived from small and heterogeneous datasets [26]. Overall, in lower extremity arthroplasty, liposomal bupivacaine demonstrates time-limited and inconsistent clinical benefit without clear superiority over conventional multimodal analgesic regimens.

In shoulder surgery, liposomal bupivacaine is most used in interscalene brachial plexus blocks, representing a mechanistically distinct approach compared with local infiltration. By targeting the neural supply to the shoulder, interscalene blocks provide more comprehensive regional analgesia, and liposomal formulations have been investigated for their potential to prolong block duration and reduce rebound pain [27]. Several randomized controlled trials and meta-analyses demonstrate improved early postoperative pain control, with reductions in pain scores and, in some cases, opioid consumption and improved patient satisfaction when used as an adjunct to standard bupivacaine [27–30]. However, these findings remain inconsistent, with other studies showing no significant differences in pain or opioid use and observed benefits often limited to early postoperative time points without sustained clinical impact [31,32]. Meta-analyses further highlight substantial heterogeneity across studies, with transient improvements that diminish over time [29]. Additionally, interscalene blockade introduces procedure-specific risks, including transient motor weakness and phrenic nerve-related effects such as hoarseness [27, 29]. Overall, across orthopedic procedures, liposomal bupivacaine demonstrates modest analgesic benefits.

Soft Tissue Surgery

In soft tissue procedures, liposomal bupivacaine demonstrates a more context-specific analgesic profile, with stronger signals of benefit in certain surgical populations but overall heterogeneous findings. This variability appears related to differences in tissue planes. Hemorrhoidectomy represents the most consistently supportive evidence base, where meta-analyses of randomized controlled trials demonstrate significant reductions in postoperative pain and opioid consumption, with sustained decreases in morphine requirements through 72 h compared with both placebo and conventional bupivacaine-based regimens [33.] Prospective studies similarly report improved pain control at rest and during defecation, reduced rescue analgesic use, and favorable tolerability profiles [34]. In inguinal hernia repair, observational data suggests reductions in postoperative opioid utilization and higher rates of opioid-free recovery, although pain score differences are less consistently demonstrated [35].

In plastic surgery, outcomes are more variable and appear dependent on procedure type and outcome definitions. In breast augmentation and reconstructive surgery, randomized and prospective studies demonstrate modest reductions in early postoperative pain and opioid consumption, with effects generally confined to the first 24 to 72 h [36, 37]. Reconstructive breast surgery may show more consistent reductions in opioid requirements and length of stay; however, systematic reviews emphasize substantial heterogeneity and inconsistent effect sizes across trials [38, 39]. Observational studies further suggest potential benefits in select populations, including improved discharge pain control and reduced antiemetic use, though findings are not uniformly replicated [40]. A retrospective abdominoplasty cohort using liposomal bupivacaine abdominal field blocks demonstrated moderate postoperative pain scores and opioid use, but interpretation is limited by its noncomparative design and incomplete follow-up [41]. Overall, soft tissue surgery demonstrates a range of evidence strength, with the most consistent opioid-sparing effects observed in hemorrhoidectomy, more variable findings in hernia repair, and heterogeneous, context-dependent outcomes in plastic surgery.

Infiltration Compared to Nerve Blocking

Given the variability in clinical efficacy across surgical contexts, differences in administration techniques have been proposed as a potential contributor to inconsistent outcomes. Liposomal bupivacaine can be administered via local infiltration at the surgical site or through peripheral nerve blockade, two techniques that differ in mechanism, distribution, and clinical application. Incisional infiltration involves direct delivery of anesthetic into the surgical field at the time of closure, targeting nociceptive input at its source and serving as a core component of multimodal analgesia strategies aimed at reducing peripheral and central sensitization [7]. In contrast, peripheral nerve blockade is performed as either a single-injection technique or a continuous catheter-based infusion [42]. Single injections are simple but short-acting, whereas catheter-based techniques provide longer analgesia but are more complex and resource-intensive [42]. Liposomal bupivacaine has been introduced as a potential intermediary, designed to extend the duration of analgesia from a single injection through sustained drug release, thereby combining the simplicity of single-shot techniques with the prolonged effect of continuous infusions [42].

Evidence for liposomal bupivacaine varies by method of administration. In surgical site infiltration, randomized trials show inconsistent benefit, with most studies failing to demonstrate significant improvement over placebo and any observed analgesic effects largely limited to the early postoperative period [6]. Procedure-specific data reflect this pattern; for example, in total knee arthroplasty, infiltration has been associated with reduced opioid consumption in the first 24 h, though these benefits are not sustained and may be accompanied by similar or higher pain scores at later time points [43]. In peripheral nerve blocks, liposomal bupivacaine has been shown to provide modest improvements in early postoperative pain control in some studies, but these effects are similarly time-limited and inconsistent across procedures. Direct comparisons between infiltration and nerve block techniques demonstrate no consistent superiority of either approach. Meta-analyses in knee and shoulder surgery show comparable postoperative pain scores and opioid consumption between liposomal bupivacaine infiltration and femoral or interscalene nerve blocks, with some studies suggesting small early opioid reductions favoring infiltration without differences in adverse events [44–47]. Similarly, randomized data in spine surgery demonstrate slight early analgesic advantages with nerve block techniques over wound infiltration, though these differences are transient and of uncertain clinical significance [48]. Overall, when defined by postoperative pain scores, opioid consumption, and recovery metrics, both techniques demonstrate comparable success rates, with differences largely confined to early postoperative intervals and specific surgical contexts.

The “Opioid-Sparing” Debate

Multimodal Analgesia: How EXPAREL Fits into Enhanced Recovery After Surgery Protocols

Liposomal bupivacaine is most incorporated into multimodal analgesia (MMA) strategies within Enhanced Recovery After Surgery (ERAS) protocols, where it functions as a long-acting regional or field anesthetic aimed at reducing opioid requirements and facilitating early recovery. Within ERAS pathways, it is typically administered as part of regional blocks or surgical site infiltration alongside non-opioid analgesics and standardized perioperative care.

Several studies suggest that its greatest benefit is realized when used as part of a comprehensive ERAS protocol rather than as a standalone intervention. In breast reconstruction, ERAS protocols incorporating liposomal bupivacaine-based regional blocks have been associated with reduced length of stay and increased rates of same-day discharge, reflecting improved perioperative recovery [49]. Similarly, in deep inferior epigastric perforator (DIEP) flap reconstruction, ERAS pathways are associated with reduced opioid consumption and hospital length of stay, with further reductions observed following the addition of liposomal bupivacaine [50]. In thoracic surgery, retrospective analyses demonstrate stepwise reductions in opioid consumption across control, liposomal bupivacaine alone, and ERAS plus liposomal bupivacaine cohorts, suggesting a potential additive effect within multimodal pathways [51]. However, not all studies demonstrate benefit; in a randomized trial of open gynecologic surgery within an ERAS protocol, liposomal bupivacaine did not significantly reduce opioid use, pain scores, or functional recovery compared to standard bupivacaine infiltration [52]. Collectively, these findings suggest that liposomal bupivacaine may contribute to ERAS-based opioid-sparing strategies, but its clinical effect is inconsistent and dependent on surgical context and protocol design.

Summary of Trials and MME Outcomes

Across surgical subspecialties, liposomal bupivacaine has demonstrated variable but often meaningful reductions in postoperative opioid consumption measured in morphine milligram equivalents (MME) (Table 1). In orthopedic populations, the effect appears most consistent. In shoulder arthroplasty, liposomal bupivacaine administered via interscalene block is associated with significantly lower opioid use at all postoperative time points, including near-zero median MME use on postoperative day (POD) 0 and 1 and substantial reductions in cumulative inpatient consumption [53]. Similarly, in total knee arthroplasty, randomized data demonstrate reduced opioid requirements in the early postoperative period (POD 0–2), driven by both decreased frequency and dose of opioid use [54]. In spine surgery, liposomal bupivacaine is associated with reduced peri-discharge MME use, although this benefit does not persist long-term [55].

Table 1.

Summary of trials involving liposomal bupivacaine

Author	Year	n	Specialty	Study design	Intervention	MME outcome	Statistical significance
Harley et al. [53]	2025	870	Orthopedics (Shoulder)	Retrospective	liposomal bupivacaine vs. standard bupivacaine (nerve block)	Reduction in MME on POD0-1 and cumulative MME	Yes (p < 0.001)
Quaye et al. [54]	2024	80	Orthopedics (TKA)	RCT	liposomal bupivacaine Adductor canal blocks (ACB) vs. conventional bupivacaine	Reduction in MME POD0–2	Yes (p < 0.05)
Berven et al. [55]	2024	1524	Orthopedics (Spine)	Propensity-matched cohort	liposomal bupivacaine vs. non-liposomal bupivacaine analgesia	Reduction in pre-discharge MME; no long-term difference	Yes pre-discharge (p=0.0041); No within 90 days (p=0.289)
Cruz et al. [35]	2021	122	Soft-tissue surgery (Inguinal hernia)	Retrospective	liposomal bupivacaine + standard protocol vs. standard	Reduction in PACU oral MME requirement; no difference in parenteral MME requirement	Yes for oral MME (p = 0.02)
Becker et al. [56]	2023	78	Soft-tissue surgery (Bariatric)	RCT	liposomal bupivacaine vs. plain bupivacaine ± ERAS	No difference in MME/day	No (p = 0.314)
Antony et al. [57]	2024	60	Soft-tissue surgery (Cesarean, TAP block)	RCT	liposomal bupivacaine + bupivacaine vs. bupivacaine	Reduced MME 48 h post-op	No (p = 0.236)
Morad et al. [58]	2020	323	Pediatrics	Retrospective	liposomal bupivacaine vs. standard analgesia	Reduced total MME and POD 0–3 use	Yes (p < 0.001)

Beyond orthopedics, findings are more heterogeneous. In abdominal surgery, studies suggest modest reductions in opioid consumption, particularly in outpatient settings, including decreased oral MME use and higher rates of opioid-free recovery following inguinal hernia repair [35]. However, this benefit is not universal. In a randomized trial of bariatric surgery patients, liposomal bupivacaine did not significantly reduce opioid use compared to standard bupivacaine, regardless of ERAS implementation [56]. Similarly, in obstetric populations, a pilot randomized trial of transversus abdominis plane (TAP) blocks demonstrated no statistically significant reduction in opioid use despite numerical trends favoring liposomal bupivacaine [57]. Pediatric studies, however, continue to demonstrate reductions in total MME consumption, pain scores, and length of stay without increased complications [58].

Overall, these findings indicate that the opioid-sparing effect of liposomal bupivacaine is highly context-dependent and influenced by surgical setting, baseline analgesic strategy, and study design. This variability is reflected in higher-level evidence. Systematic reviews and meta-analyses, including those in thoracic surgery, have generally failed to demonstrate a consistent reduction in postoperative MME use with liposomal bupivacaine compared to controls, with substantial heterogeneity across studies [59]. In contrast, meta-analyses within ERAS pathways suggest that liposomal bupivacaine-based techniques, particularly TAP blocks and local infiltration, may rank among the more effective opioid-sparing strategies, although the overall certainty of evidence remains low [60].

Liposomal Bupivacaine Versus Bupivacaine with Adjuvants

The limitations of liposomal bupivacaine become most apparent in studies comparing it to conventional bupivacaine combined with adjuvants such as dexamethasone or epinephrine. In these optimized regimens, liposomal bupivacaine frequently fails to demonstrate superiority. In orthopedic surgery, randomized trials of interscalene brachial plexus blocks show that liposomal bupivacaine is non-inferior but not superior to bupivacaine with dexamethasone, with no differences in postoperative opioid consumption, pain scores, or block duration [61]. Similarly, a triple-blinded randomized trial in total shoulder arthroplasty comparing liposomal bupivacaine, dexamethasone-enhanced bupivacaine, and continuous catheter techniques found no significant differences in analgesic outcomes across groups, suggesting that adjuvants may prolong the duration of conventional local anesthetics and reduce any incremental benefit of liposomal bupivacaine [62]. A similar finding is observed with epinephrine-containing regimens. In a randomized trial of minimally invasive lung resection, no differences were observed in postoperative opioid consumption or pain scores between liposomal bupivacaine and bupivacaine with epinephrine [63]. Overall, these studies indicate that liposomal bupivacaine offers limited additional analgesic benefit when compared against optimized local anesthetic regimens. This supports the interpretation that the effectiveness of liposomal bupivacaine is context-dependent rather than inherently superior.

Administration and Best Practices

Proper administration techniques and adherence to established guidelines are essential for maximizing the clinical effectiveness of liposomal bupivacaine. With an FDA-approved maximum infiltration dose of 266 mg, targeted distribution is critical to ensure adequate tissue coverage and effective analgesia [64]. In a randomized controlled trial of patients undergoing total knee arthroplasty, liposomal bupivacaine PAI demonstrated comparable outcomes to bupivacaine hydrochloride adductor canal blocks (ACBs) in postoperative pain, knee range of motion, ambulation, and opioid use [65]. By enabling infiltration throughout the entire knee capsule, liposomal bupivacaine-PAI achieves broader local tissue coverage while maintaining adequate analgesia, maximizing surface area exposure within a confined injection site [65]. In contrast, ACBs primarily target the medial compartment of the knee, leaving the lateral and posterior compartments untreated [66]. Additionally, liposomal bupivacaine demonstrates versatility with multiple acceptable infiltration sites (e.g. field, perilesional, intradermal, subcutaneous), supporting analgesia across various procedures [67, 68].

Volume expansion is another key consideration to ensure adequate tissue coverage across varying site sizes. Dilution with normal saline up to 300 mL does not alter its pharmacokinetic profile or analgesic efficacy, allowing effective coverage of larger surgical sites without compromise [69]. By expanding the volume, clinicians can cover larger surgical sites uniformly and reduce the risk of suboptimal postoperative pain control.

Attention to drug-drug interactions is equally important to avoid contraindications and maintain effective postoperative pain control. Specifically, administration of liposomal bupivacaine should be delayed by at least 20 min following lidocaine injection to prevent premature free bupivacaine release from liposomes [70]. Co-administration with antiseptics is also not recommended due to potential rapid systemic release of bupivacaine and increased risk of LAST [64]. Other local anesthetics should generally be avoided within 96 h following liposomal bupivacaine administration [71]. Monitoring toxicity thresholds and adherence to clinical guidelines can help preserve its sustained analgesic properties and optimize patient outcomes. Further pharmacokinetic and clinical safety studies are warranted to investigate additional drug-drug interactions and minimize risk of systemic toxicity.

Patient-Centered Outcomes

When assessing the overall effectiveness of liposomal bupivacaine as an alternative or adjunct agent in a multimodal based analgesic approach, one should evaluate its impact on various patient-centered outcomes Ultimately, liposomal bupivacaine demonstrates context specific benefits on various patient recovery milestones which vary widely based on surgical approach. This is most evident when compared to epidural analgesia and continuous nerve blocks, however no clear benefits have consistently been shown when compared to standard bupivacaine formulations.

Time to Ambulation

The use of liposomal bupivacaine compared to standard formulations of local anesthetics demonstrates variable outcomes regarding time to ambulation. In a TKA, PAI of liposomal bupivacaine was associated with an earlier time to ambulation compared to femoral nerve block, as well as an increased ambulation distance on both the day of surgery and post-operative day one [72, 73]. Similarly, several studies in thoracic surgery have indicated an improved time to ambulation with the use of liposomal bupivacaine via intercostal, erector spinae plane, and paravertebral blocks compared to standard formulations of either bupivacaine or ropivacaine [74–76]. However, a 2026 meta-analysis of nine RCTs comparing the efficacy of liposomal bupivacaine versus non-liposomal local anesthetics refuted this claim, finding no significant difference in time to first ambulation, length of stay, overall opioid consumption, or overall pain scores [77].

Length of Stay/Time to Discharge Readiness

The effect of liposomal bupivacaine on time to discharge and overall hospital length of stay is even more inconsistent. Some studies involving thoracic surgery, lumbar fusion, and colorectal surgery have shown encouraging results with significantly reduced overall length of stay with the use of liposomal bupivacaine versus standard formulations of local anesthetics in these various surgical contexts [60, 74, 78]. The most compelling evidence for the use of liposomal bupivacaine comes with radical cystectomy, where local infiltration as opposed to epidural anesthesia not only demonstrated a significantly reduced overall length of stay, but also resulted in a decreased total opioid consumption rate, earlier diet advancement, and improved cost effectiveness [79]. Conversely, other studies have shown no benefit in time to discharge readiness, including the most complete, highest quality RCT to date involving four types of truncal incisions following cardiothoracic surgery which found no difference in hospital length of stay, overall pain scores, or total opioid use between local infiltration of liposomal bupivacaine compared to standard bupivacaine [72, 80].

Patient Satisfaction Scores

While there is an abundance of evidence showing that liposomal bupivacaine improves patient satisfaction and overall post-operative recovery scores when compared to placebo, this advantage largely disappears when compared to standard bupivacaine [52, 81–84]. In 2025, a group of researchers set out to assess the efficacy of liposomal bupivacaine on overall post-operative recovery by evaluating quality of recovery (QoR) scores, a metric designed to represent the restoration of one’s physical and psychological recovery after surgery. This meta-analysis of 11 RCTs concluded that the use of liposomal bupivacaine not only improved QoR scores, but also significantly increased patient satisfaction scores, reduced incidence of post-operative nausea and vomiting (PONV), and decreased total opioid consumption [84]. Despite these encouraging results, it must be noted that the largest comprehensive review of 76 RCTs comparing the use of liposomal bupivacaine versus standard formulations of local anesthetics ultimately found that 84% of trials at a high risk of bias reported statistical significance in favor of liposomal bupivacaine whereas only 14% of trials at a low risk of bias reported statistical significance [6].

Post-Operative Sleep Quality

There is mixed evidence of the impact of liposomal bupivacaine on overall sleep quality. Several RCTs, primarily within the field of orthopedic surgery, report improved sleep quality and statistically significant higher sleep scores with the use of liposomal bupivacaine versus ropivacaine, particularly on POD 1 and 2 [85–87]. Others within the fields of bariatric and spine surgery report no such benefit [88, 89]. Ultimately, this modest improvement in sleep quality/scores is likely a result of improved pain scores, decreased PONV, and other improved recovery metrics often described with the use of liposomal bupivacaine rather than a direct effect on sleep architecture itself [43, 84]. Regardless, as previously discussed, these factors contributing towards improved sleep are often variable, inconsistent, and context-specific at best.

Economic Analysis

While liposomal bupivacaine has been utilized as a potential opioid-sparing alternative for postoperative pain management, its economic impact remains an important consideration. Currently, liposomal bupivacaine is associated with a higher upfront acquisition cost compared with other local anesthetic agents, exceeding $350 for a single 266-mg vial [65]. Since its approval by the U.S. Food and Drug Administration in 2011, reported costs have increased from an initial estimate of $285 per vial [90, 91].

Despite these cost considerations, its role in pain management continues to gain attention, particularly as an alternative to traditional opioid use and in reducing opioid-related adverse events (ORAEs) [92]. Several studies have reported reductions in ORAEs (e.g., respiratory depression, sedation, postoperative ileus, nausea, pruritus, vomiting, and urinary retention) and total opioid consumption with liposomal bupivacaine-based multimodal analgesia compared with intravenous opioid patient-controlled analgesia (PCA), although statistical significance has not been consistently demonstrated across studies [93–95]. By reducing the incidence of ORAEs, liposomal bupivacaine may help mitigate postoperative complications and decrease the need for additional medical interventions, lowering hospitalization costs and healthcare utilization [96]. In a prospective randomized controlled study, its use was also associated with significant reductions in total opioid consumption, postoperative pain scores, and ORAEs compared with a PCA-dependent cohort [97]. Decreases in opioid consumption, healthcare demand due to adverse effects of opioid use, and reliance on PCA pumps represent indirect benefits that can help offset its higher upfront cost.

Recent literature evaluating the cost-effectiveness of liposomal bupivacaine has yielded inconclusive results. Several studies suggest potential economic benefit and lower overall patient costs in select surgical populations. For example, in a retrospective observational study involving patients with intertrochanteric hip fractures, intraoperative liposomal bupivacaine use was associated with increased rates of discharge to home and a benefit-cost ratio of 3.95, corresponding to $3.95 in savings for every $1 invested and a net benefit of $1,323.21 per patient [98]. Similarly, in total knee arthroplasties, its use has been associated with reduced hospital length of stay, earlier postoperative ambulation, and decreased nonsteroidal anti-inflammatory drug utilization [73]. In colorectal surgery, liposomal bupivacaine has also been associated with reductions in total cost of care despite higher upfront drug costs, driven in part by shorter hospital stays and decreased need for postoperative ileus management [99].

However, these findings are not consistent across all settings, suggesting the influence of additional factors. In a single-blind randomized study of early-stage lung cancer patients undergoing minimally invasive lobectomy, liposomal bupivacaine demonstrated no significant differences compared to standard bupivacaine in surgery duration, chest tube duration, short-term and long-term narcotic use, postoperative pain scores, or length of stay [100]. Similarly, a large database study of 18,817 patients undergoing total knee arthroplasty found no clinically significant reductions in inpatient opioid use, length of stay, or opioid-related adverse events associated with liposomal bupivacaine [101].

Given these mixed findings, the cost-effectiveness of liposomal bupivacaine appears to be highly context-dependent, varying by surgical procedure, institutional protocols, and administration techniques. These factors likely reflect the multifactorial nature of perioperative pain management and support its selective use rather than as a universal alternative to opioids. Further research using larger, standardized cohorts and consistent administration protocols across institutions is needed to better define its economic role and identify specific patient populations and procedures most likely to benefit. Ultimately, balancing effective, sustainable pain control with minimization of ORAEs, healthcare costs, and resource utilization is essential for optimizing perioperative pain management.

Future Directions and Conclusions

The expanding use of liposomal bupivacaine reflects the ongoing evolution of perioperative pain management toward opioid-sparing, multimodal analgesic strategies. Since its initial approval, additional clinical applications have been explored across a broad range of surgical specialties and regional anesthesia techniques. Ongoing research continues to evaluate its role in novel block approaches, procedure-specific analgesic pathways, and potentially chronic pain management strategies. Future investigations will be important in identifying specific patient populations and surgical procedures most likely to derive meaningful benefit from extended-release local anesthetic formulations.

Despite its theoretical advantages and widespread adoption, current evidence suggests that liposomal bupivacaine should not be viewed as a universal replacement for conventional local anesthetics or opioid-based analgesia. While some studies demonstrate improvements in postoperative pain control, opioid consumption, and recovery metrics, others show minimal or no clinically meaningful advantage compared with standard bupivacaine or optimized multimodal analgesic regimens. Differences in study design, surgical procedure, administration technique, comparator groups, and institutional protocols likely contribute to the heterogeneity observed across literature.

Ultimately, liposomal bupivacaine represents a specialized tool within a broader multimodal analgesic framework rather than a “silver bullet” for postoperative pain management. Its greatest value may be realized when patient selection, surgical factors, and administration technique are carefully considered to maximize tissue coverage and therapeutic benefit. Future high-quality, adequately powered studies using standardized protocols and clinically meaningful outcomes are needed to further define its role in contemporary perioperative care. A more individualized approach will be essential to balance analgesic efficacy, opioid reduction, safety, and cost-effectiveness.

Key References

• Hamilton TW, Athanassoglou V, Mellon S, et al. Liposomal bupivacaine infiltration at the surgical site for the management of postoperative pain. Cochrane Database Syst Rev. 2017;2017(2):CD011419. doi:10.1002/14651858.CD011419.pub2

  • ○ Liposomal bupivacaine may reduce postoperative pain compared to placebo, it does not consistently demonstrate superiority over bupivacaine hydrochloride.
• Nguyen A, Grape S, Gobbetti M, Albrecht E. The postoperative analgesic efficacy of liposomal bupivacaine versus long-acting local anaesthetics for peripheral nerve and field blocks: A systematic review and meta-analysis, with trial sequential analysis. Eur J Anaesthesiol. 2023;40(9):624-635. doi:10.1097/EJA.0000000000001833

  • ○ Recent meta-analysis suggest modest improvements in pain scores persisting up to 72 hours, though without corresponding reductions in opioid consumption

Author Contributions

R.B. contributed most to the manuscriptJ.Z. contributed to the manuscriptL.A. contributed to the manuscriptR.W. contributed to the manuscriptC.R. edited the manuscriptA.N. contributed to and edited the manuscript.

Data Availability

No datasets were generated or analysed during the current study.

Declarations

Competing Interests

The authors declare no competing interests.